Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | ClonoSEQ: evaluating MRD in CLL

Nitin Jain • 17 Sep 2020
SOHO 2020
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the importance of minimal residual disease (MRD) measurement in chronic lymphocytic leukemia (CLL), especially those treated with combination BTK inhibitor and venetoclax. Dr Jain outlines next-generation sequencing assays for MRD, including the ClonoSEQ assay, recently approved for clinical use in CLL patients by the FDA. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nitin Jain

1:13
5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax
Nitin Jain • 10 Dec 2023
1:06
An ongoing Phase I trial evaluating AS-1763, a novel non-covalent BTKi, in B-cell lymphomas
Nitin Jain • 10 Dec 2023
1:43
Long-term outcomes of the iFCG regimen for firstline treatment of patients with IGHV-mutated CLL
Nitin Jain • 10 Dec 2023
1:54
Nivolumab + ibrutinib for patients with Richter’s transformation
Nitin Jain • 7 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals